Annexin Pharmaceuticals AB (FRA:Q910) Tariff Resilience Score: 0/10 (As of Jul. 10, 2026)


FRA:Q910 Annexin Pharmaceuticals AB FRA:Q910
13 GF Score
Price €1.13
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB Tariff Resilience Score?

Annexin Pharmaceuticals AB has the Tariff Resilience Score of 0, which implies that the company might have .

Annexin Pharmaceuticals AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Annexin Pharmaceuticals AB might have .

Annexin Pharmaceuticals AB  (FRA:Q910) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Annexin Pharmaceuticals AB Tariff Resilience Score Related Terms

FRA:Q910
13GF Score
Annexin Pharmaceuticals AB FRA:Q910
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB Business Description

Other Exchanges ANNX:Sweden
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
13GF Score

Get the complete analysis for FRA:Q910

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.13
Price